

Appointment and resignation of Non-Executive Director

Sydney, Australia – 4 April 2022: Cannabis focused drug development and product innovation company Bod Australia Limited (“Bod” or “the Company”) (ASX: BOD) advises that Mr Simon O’Loughlin has retired as a Non-Executive Director.

Mr O’Loughlin has been a Board member since 2016 and was instrumental in the company’s ASX-listing and growth trajectory. Bod has considerably benefitted from Mr O’Loughlin’s extensive expertise, guidance and advice in recent years. The Company wishes him well for his future endeavours.

Mr O’Loughlin will be replaced by Mr David Baker. Mr Baker has been appointed as a Non-Executive Director effective 4 April 2022.

Mr Baker is a commercial advisor and company director with over 40 years’ experience in law, investment banking, public company leadership and corporate governance. He has deep industry knowledge across a range of sectors and a sophisticated understanding of financial markets.

Mr Baker is a co-founder of Baker Cook Advisory which is a boutique provider of outsourced legal, commercial and governance advice and mediation services for corporations and government agencies.

Mr Baker is also a longstanding shareholder in the Company. Additional details of his shareholding are contained in the Appendix 3X which accompanies this announcement.

Bod expects to benefit from Mr Baker’s extensive expertise and corporate governance acumen as it continues to advance its clinical trial pathways and drug development initiatives.

Non-Executive Chairman Mr Mark Masterson said: *“On behalf of the Board and management, I would like to thank Simon for his service and dedication to Bod Australia. He has assisted Bod through a number of major milestones and been a constant supporter of the Company. We wish him the best for his future endeavours.*

“We are also very pleased to welcome David to the Board. He has been a supportive shareholder for many years and his expertise across public companies and financial markets will be beneficial for Bod as it continues to pursue clinical trial objectives and product commercialisation opportunities.”

This announcement has been approved by the Board of Bod Australia Limited.

-ENDS-

About Bod Australia:

Bod Australia Limited (ASX:BOD) Bod is a cannabis centric global life science healthcare company.

With a focus and mission to innovate and transform the way we live and enjoy life.

Delivering premium, proven and trusted products for both the consumer markets and medical markets.

Leading the way in research and development, including collaborations with research partners on clinical trial programs.

For more information please contact:

Jo Patterson
Chief Executive Officer
Info@bodaustralia.com
+61 2 9199 5018

Henry Jordan
Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 431 271 538

CONTACT

T +61 2 9199 5018 E info@bodaustralia.com bodaAustralia.com